MannKind eyes pediatric market with INHALE-1ST trial and upcoming FDA verdict
MannKind (NASDAQ:MNKD) announced a major clinical milestone Monday, enrolling the first patient in its INHALE-1ST study just as it prepares for a transformative FDA decision that could introduce the first needle-free insulin for children in over a century.





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













